Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ: NAMS ) 20.09 +0.04 (+0.20%) Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about NewAmsterdam Pharma Company N.V. - Ordinary Shares < Previous 1 2 Next > NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results May 09, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 May 02, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease April 09, 2024 Enrollment to continue to the end of April to accommodate strong patient and site interest From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer April 01, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress March 25, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD March 12, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update February 28, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March February 26, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants February 13, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants February 13, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors January 08, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces 2024 Strategic Priorities January 04, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights November 13, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer October 23, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation September 21, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference September 20, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer August 14, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights August 07, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease July 25, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares June 09, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares June 06, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares June 06, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients June 05, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 June 03, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma to Present at Jefferies Healthcare Conference May 31, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023 May 23, 2023 NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights May 08, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia April 24, 2023 From NewAmsterdam Pharma Company B.V. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.